Aliases & Classifications for Adenoma

MalaCards integrated aliases for Adenoma:

Name: Adenoma 12 52 14 69
Acinar Cell Adenoma 12 69
Acinic Cell Adenoma 12
Adenomas 12

Classifications:



External Ids:

Disease Ontology 12 DOID:657
MeSH 42 D000236
NCIt 47 C2855 C4196

Summaries for Adenoma

Disease Ontology : 12 A cell type benign neoplasm that is composed_of epithelial tissue in which tumor cells form glands or glandlike structures.

MalaCards based summary : Adenoma, also known as acinar cell adenoma, is related to pituitary adenoma, acth-secreting and pituitary adenoma, prolactin-secreting. An important gene associated with Adenoma is PLAG1 (PLAG1 Zinc Finger), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Signaling in Gap Junctions. The drugs Erythromycin and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include pituitary, colon and thyroid, and related phenotypes are Increased shRNA abundance (Z-score > 2) and cellular

Wikipedia : 72 An adenoma (from Greek αδένας, adeno-, \"gland\" + -ώμα, -oma, \"tumor\") (/ˌædɪˈnoʊmə/; plural adenomas... more...

Related Diseases for Adenoma

Diseases related to Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 716)
id Related Disease Score Top Affiliating Genes
1 pituitary adenoma, acth-secreting 34.3 AIP GNAS PRL SST
2 pituitary adenoma, prolactin-secreting 34.3 AIP GNAS PRL SST
3 apocrine adenoma 33.5 BRAF CCND1 KRAS MLH1 MSH2
4 wolffian duct adenoma 33.4 GNAS KRAS MLH1 MSH2
5 parathyroid oncocytic adenoma 33.4 CCND1 CTNNB1 RET
6 mismatch repair cancer syndrome 32.1 CTNNB1 MLH1 MSH2
7 colorectal cancer 30.8 AXIN2 BRAF CCND1 CTNNB1 GNAS KRAS
8 apocrine adenocarcinoma 30.3 CCND1 CTNNB1 KRAS
9 fibroma 30.3 BRAF GNAS KRAS SST
10 microscopic colitis 30.0 CTNNB1 MLH1 MSH2 SMAD4
11 psoriasis 30.0 MLH1 MSH2
12 gallbladder cancer 29.5 CCND1 CTNNB1 KRAS MLH1 MSH2 SMAD4
13 adrenal cortical carcinoma 29.3 CCND1 CTNNB1 KRAS SMAD4 SST TGFBR2
14 sertoli-leydig cell tumor 28.5 BRAF CCND1 CTNNB1 KRAS MLH1 MSH2
15 pituitary adenoma 12.3
16 adrenal adenoma 12.1
17 parathyroid adenoma 12.1
18 pituitary adenoma, growth hormone-secreting 12.1
19 pleomorphic adenoma 12.1
20 hepatocellular adenoma 12.1
21 colorectal adenoma 12.1
22 villous adenoma 12.1
23 aldosterone-producing adenoma 12.0
24 sebaceous adenoma 12.0
25 familial isolated pituitary adenoma 12.0
26 nephrogenic adenoma 12.0
27 adrenal cortical adenoma 12.0
28 hepatic adenoma, somatic 12.0
29 metanephric adenoma 12.0
30 clear cell adenoma 11.9
31 water-clear cell adenoma 11.9
32 eccrine papillary adenoma 11.9
33 prostatic adenoma 11.8
34 adenomas, multiple colorectal 11.8
35 pituitary adenoma, growth hormone-secreting 2 11.8
36 follicular adenoma 11.8
37 chromophobe adenoma 11.8
38 papillary adenoma 11.8
39 microcystic adenoma 11.8
40 lung adenoma 11.8
41 middle ear adenoma 11.8
42 aip-related familial isolated pituitary adenomas 11.8
43 functioning pituitary adenoma 11.8
44 intrahepatic bile duct adenoma 11.8
45 oxyphilic adenoma 11.8
46 acidophil adenoma 11.8
47 basophil adenoma 11.8
48 renal adenoma 11.8
49 colon adenoma 11.8
50 gallbladder adenoma 11.7

Graphical network of the top 20 diseases related to Adenoma:



Diseases related to Adenoma

Symptoms & Phenotypes for Adenoma

GenomeRNAi Phenotypes related to Adenoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.6 SMAD4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.6 SMAD4 TGFBR2 CTNNB1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.6 PLAGL2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.6 CTNNB1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.6 TGFBR2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.6 TGFBR2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.6 TGFBR2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.6 CCND1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.6 PLAGL2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.6 RET
11 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.6 RET TGFBR2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.6 PLAGL2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.6 TGFBR2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.6 CCND1 TGFBR2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.6 CCND1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.6 TGFBR2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.6 CCND1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.6 RET TGFBR2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.6 RET
20 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.6 CCND1 CTNNB1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.6 TGFBR2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-188 10.6 TGFBR2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.6 CTNNB1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.6 CCND1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.6 SMAD4 CCND1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.6 CCND1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.6 TGFBR2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.6 SMAD4 RET CCND1 PLAGL2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.6 CCND1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.6 TGFBR2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.6 SMAD4
32 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.6 SMAD4
33 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.6 SMAD4
34 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.6 CTNNB1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.6 CTNNB1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.6 RET
37 Increased shRNA abundance (Z-score > 2) GR00366-A-54 10.6 SMAD4
38 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.6 PLAGL2
39 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.6 CTNNB1
40 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.6 TGFBR2
41 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.6 PLAGL2 RET SMAD4 TGFBR2 CTNNB1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.6 SMAD4 CTNNB1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.6 CTNNB1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.6 PLAGL2 SMAD4 TGFBR2
45 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.6 RET
46 Decreased viability GR00055-A-2 10.16 BRAF KRAS
47 Decreased viability GR00106-A-0 10.16 KRAS
48 Decreased viability GR00221-A-1 10.16 KRAS RET
49 Decreased viability GR00221-A-2 10.16 KRAS RET
50 Decreased viability GR00221-A-4 10.16 RET BRAF
51 Decreased viability GR00231-A 10.16 RET
52 Decreased viability GR00301-A 10.16 KRAS MSH2 RET BRAF
53 Decreased viability GR00381-A-1 10.16 KRAS BRAF
54 Decreased viability in esophageal squamous lineage GR00235-A 9.93 TGFBR2 THADA AXIN2 BRAF CCND1 CTNNB1
55 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.17 AXIN2 BRAF GNAS MSH2 PLAGL2 SMAD4

MGI Mouse Phenotypes related to Adenoma:

44 (show all 23)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.47 AIP AXIN2 BRAF CCND1 CTNNB1 GNAS
2 growth/size/body region MP:0005378 10.46 KRAS LHCGR PLAG1 PLAGL1 PLAGL2 RET
3 homeostasis/metabolism MP:0005376 10.45 CTNNB1 GNAS KRAS LHCGR MLH1 MSH2
4 endocrine/exocrine gland MP:0005379 10.44 GNAS KRAS LHCGR MLH1 PLAG1 PRL
5 digestive/alimentary MP:0005381 10.4 BRAF CCND1 CTNNB1 KRAS LHCGR MLH1
6 mortality/aging MP:0010768 10.38 TGFBR2 AIP AXIN2 BRAF CCND1 CTNNB1
7 behavior/neurological MP:0005386 10.35 BRAF CCND1 CTNNB1 GNAS KRAS LHCGR
8 cardiovascular system MP:0005385 10.35 AIP AXIN2 BRAF CCND1 CTNNB1 GNAS
9 immune system MP:0005387 10.31 BRAF CCND1 CTNNB1 GNAS KRAS LHCGR
10 embryo MP:0005380 10.27 TGFBR2 AIP AXIN2 BRAF CTNNB1 KRAS
11 integument MP:0010771 10.26 AIP BRAF CCND1 CTNNB1 GNAS KRAS
12 nervous system MP:0003631 10.25 AXIN2 RET BRAF SMAD4 CCND1 SST
13 neoplasm MP:0002006 10.23 AIP BRAF CCND1 CTNNB1 GNAS KRAS
14 craniofacial MP:0005382 10.19 AXIN2 BRAF CCND1 CTNNB1 GNAS KRAS
15 limbs/digits/tail MP:0005371 10.11 AXIN2 CTNNB1 GNAS KRAS LHCGR PLAGL1
16 liver/biliary system MP:0005370 10.1 AIP BRAF CTNNB1 GNAS KRAS PRL
17 normal MP:0002873 10.07 CTNNB1 GNAS KRAS RET SMAD4 SST
18 reproductive system MP:0005389 10 AXIN2 BRAF CCND1 CTNNB1 KRAS LHCGR
19 no phenotypic analysis MP:0003012 9.95 CTNNB1 GNAS KRAS PLAGL1 RET SST
20 renal/urinary system MP:0005367 9.87 BRAF CTNNB1 GNAS KRAS LHCGR RET
21 respiratory system MP:0005388 9.81 BRAF CCND1 CTNNB1 GNAS KRAS MLH1
22 skeleton MP:0005390 9.7 AXIN2 BRAF CCND1 CTNNB1 GNAS KRAS
23 vision/eye MP:0005391 9.23 AXIN2 BRAF CCND1 CTNNB1 KRAS MLH1

Drugs & Therapeutics for Adenoma

Drugs for Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 546)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Erythromycin Approved, Vet_approved Phase 4 114-07-8 12560
2
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
3
Pantoprazole Approved Phase 4 102625-70-7 4679
4
Ticlopidine Approved Phase 4 55142-85-3 5472
5
Ecabet Approved, Investigational Phase 4 33159-27-2, 86408-72-2 65781
6 Magnesium citrate Approved Phase 4,Phase 3,Phase 2
7
Magnesium oxide Approved Phase 4 1309-48-4 14792
8
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2 51-43-4 5816
9 Racepinephrine Approved Phase 4,Phase 3,Phase 2
10
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-23-7 5754 657311
11
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
12
Menthol Approved Phase 4,Phase 3,Phase 1,Phase 2 2216-51-5 16666
13
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83150-76-9 383414 6400441
14
Cabergoline Approved Phase 4,Phase 3,Phase 2 81409-90-7 54746
15
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
16
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 6442177
17
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
18
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
19
Metformin Approved Phase 4,Phase 2,Phase 1 657-24-9 14219 4091
20
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
21
Somatostatin Approved Phase 4,Phase 2,Phase 3,Phase 1 38916-34-6, 51110-01-1 53481605
22
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 169590-42-5 2662
23 lanreotide Approved Phase 4,Phase 3,Phase 2 108736-35-2
24
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
25
Cefazolin Approved Phase 4 25953-19-9 656510 33255
26
Cefdinir Approved Phase 4 91832-40-5 6915944
27
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
28
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
29
Sulfamethoxazole Approved Phase 4 723-46-6 5329
30
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
31
Liraglutide Approved Phase 4 204656-20-2 44147092
32
Zinc Approved Phase 4,Phase 3 7440-66-6 32051 23994
33
Clarithromycin Approved Phase 4 81103-11-9 84029
34
Clopidogrel Approved, Nutraceutical Phase 4 120202-66-6, 113665-84-2 60606
35
Vitamin C Approved, Nutraceutical Phase 4,Phase 3,Phase 2 50-81-7 5785 54670067
36
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
37
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 58-05-9 143 6006
38
Butyric Acid Experimental Phase 4 107-92-6 264
39 Pancreatic Polypeptide Investigational Phase 4,Phase 2,Phase 3,Phase 1 59763-91-6
40
Lactitol Investigational Phase 4 585-86-4 3871
41 Adjuvants, Anesthesia Phase 4,Phase 3,Phase 1
42 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
43 Anticonvulsants Phase 4,Phase 2
44 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
45 Bromides Phase 4
46 Butylscopolammonium Bromide Phase 4
47 Cholinergic Agents Phase 4
48 Cholinergic Antagonists Phase 4
49 Muscarinic Antagonists Phase 4
50 Mydriatics Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 1107)

id Name Status NCT ID Phase Drugs
1 Does the Hyoscine N-Butylbromide Administered During Colonoscopy Increase the Adenoma Detection Rate? Unknown status NCT01609855 Phase 4 Hyoscine Butyl Bromide 20mg/2 ml i.v.;Saline 2 ml i.v.
2 Efficacy Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia Unknown status NCT01767870 Phase 4
3 Prophylactic Pancreatic Duct Stent Placement After ESP of Major Papillary Tumors; Prospective, Randomized Study Unknown status NCT01737463 Phase 4
4 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
5 Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy Unknown status NCT01739608 Phase 4
6 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
7 Efficacy of Ecabet Sodium and Proton Pump Inhibitor Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection Unknown status NCT01308177 Phase 4 Ecabet
8 Efficacy and Safety of Split-dose Citrafleet Administered From 2 to 6 Hours Before Morning Colonoscopies Unknown status NCT01481714 Phase 4 Sodium picosulphate, magnesium oxid and citric acid;Sodium picosulphate/magnesium oxide and citric acid
9 Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism Unknown status NCT02127840 Phase 4 Synacthen infusion during adrenal venous sampling
10 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
11 Characterization of Receptors in Non-functioning Pituitary Macroadenomas Unknown status NCT00852501 Phase 4
12 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
13 Endoscopy Nurse Participation in Adenoma Detection Rate During Colonoscopy Completed NCT01124266 Phase 4
14 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
15 Comparative Efficacy of Water & Indigo Carmine vs. Water or Air Method on Adenoma Detection Rate (ADR) - a Randomized Controlled Trial (RCT) Completed NCT01607255 Phase 4 Indigo carmine
16 Effect of Gum Chewing on Bowel Cleansing Before Colonoscopy Completed NCT02507037 Phase 4 polyethylene glycol
17 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
18 A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate) Completed NCT01689792 Phase 4 MOVIPREP;CitraFleet
19 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
20 Holmium Laser Enucleation of Prostate(HOLEP) vs Greenlight(XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP) Completed NCT01494337 Phase 4
21 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
22 Evaluation of the Effects of Different Prostate Surgeries on Urinary and Sexual Function Completed NCT01810068 Phase 4
23 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
24 Oral Sulfate Solution (SUPREP) Versus Polyethylene Glycol (PEG) Plus Ascorbic Acid Completed NCT02761213 Phase 4 Oral sulfate solution (OSS);2-L PEG/Asc
25 Cardiac Valve Complications in Prolactinomas Treated With Cabergoline Completed NCT00460616 Phase 4 Cabergoline
26 Comparative Study of Postprocessing Imaging Systems for Diminutive Colonic Polyps Completed NCT01133041 Phase 4
27 Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding Recruiting NCT02032784 Phase 4 octreotide
28 Transanal Endoscopic Microsurgery Versus Endoscopic Submucosal Dissection For Large Rectal Adenomas Recruiting NCT01023984 Phase 4
29 Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD. Recruiting NCT02638584 Phase 4 Ilaprazole;Rabeprazole
30 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
31 Glucagon and Colonoscopy Recruiting NCT02078726 Phase 4 Glucagon;Placebo
32 Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly Recruiting NCT02115906 Phase 4
33 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
34 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Recruiting NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
35 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
36 Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp Recruiting NCT03065868 Phase 4 H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)
37 GreenLight Laser Photoselective Vaporization of the Prostate vs Plasma Kinetic Vaporization of the Prostate; RCT Active, not recruiting NCT02283684 Phase 4
38 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4 sunitinib
39 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
40 Impact of Reinforced Education by Wechat and Short Message Service on the Quality of Bowel Preparation Not yet recruiting NCT02832869 Phase 4
41 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version Not yet recruiting NCT02354560 Phase 4 Erythromycin
42 Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens Not yet recruiting NCT03298945 Phase 4 Miralax-Gatorade Prep;Golytely
43 A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED) Terminated NCT00140894 Phase 4 MK0966; rofecoxib / Duration of Treatment: 24 weeks;Comparator: placebo / Duration of Treatment: 24 weeks
44 Single Arm Post-marketing Study of SC20 Colonoscope Terminated NCT02279836 Phase 4
45 Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients Terminated NCT00151476 Phase 4 Celecoxib
46 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
47 Effectiveness of Instillation of Blue Water (Indigo Carmin®) for Colonoscopy Unknown status NCT01937429 Phase 3
48 Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients Unknown status NCT00134758 Phase 2, Phase 3 Ursodeoxycholic acid;Placebo
49 Evaluation of Flexible Sigmoidoscopy Screening as an Adjunct to the National FOBT Screening Programme in Scotland Unknown status NCT02560194 Phase 3
50 Efficacy of Bispectral Index Monitoring for Midazolam and Meperidine Induced Sedation During Endoscopic Submucosal Dissection Unknown status NCT01157598 Phase 3

Search NIH Clinical Center for Adenoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Adenoma

Anatomical Context for Adenoma

MalaCards organs/tissues related to Adenoma:

39
Pituitary, Colon, Thyroid, Lung, Prostate, Salivary Gland, Testes

Publications for Adenoma

Articles related to Adenoma:

(show top 50) (show all 7417)
id Title Authors Year
1
Hepatocellular adenoma: Classification, variants and clinical relevance. ( 28131467 )
2017
2
The Effects of Platelet-Rich Fibrin Membrane on Secondary Healing After Pleomorphic Adenoma Excision in the Hard Palate: A Preliminary Study. ( 28713740 )
2017
3
Thyrotropin-producing pituitary adenoma simultaneously existing with Graves' disease: a case report. ( 28061802 )
2017
4
Sebaceous adenoma arising in mature cystic teratoma of the ovary. Case report. ( 28248120 )
2017
5
Pituitary adenoma with adipose tissue: A new metaplastic variant. ( 28070930 )
2017
6
Diffuse hematoma caused by spontaneous rupture of a parathyroid adenoma: a case report. ( 28728949 )
2017
7
A Case of Pituitary Carcinoma Initially Diagnosed as an Ectopic Growth Hormone Producing Pituitary Adenoma with a High Ki-67 Labeling Index. ( 28586933 )
2017
8
Incidence of malignant tumours in patients with a non-functioning pituitary adenoma. ( 28274953 )
2017
9
Re: Endoscopically-assisted extracapsular dissection of pleomorphic adenoma of the parotid gland through a postauricular sulcus approach in young patients. ( 28735635 )
2017
10
EZH2 copy number and mutational analyses in sporadic parathyroid adenomas. ( 27738890 )
2017
11
Characteristics of Japanese aldosterone-producing adenomas with KCNJ5 mutations. ( 27681703 )
2017
12
Protean Presentations of Parathyroid Adenoma in Childhood. ( 28082776 )
2017
13
Short-term outcomes of laparoscopic vs. open liver resection for hepatocellular adenoma: a multicenter propensity score adjustment analysis by the AFC-HCA-2013 study group. ( 28281121 )
2017
14
Decrease in size and activity of parathyroid adenoma after ultrasound guided biopsy. ( 28914043 )
2017
15
Association of plasma C-reactive protein level with the prevalence of colorectal adenoma: the Colorectal Adenoma Study in Tokyo. ( 28667300 )
2017
16
Case report: ACTH-secreting pituitary carcinoma metastatic to the liver in a patient with a history of atypical pituitary adenoma and Cushing's disease. ( 28420444 )
2017
17
Parathyroid carcinoma in a patient with three prior parathyroid adenomas. ( 28636744 )
2017
18
Multihormonal pituitary adenoma concomitant with Pit-1 and Tpit lineage cells causing acromegaly associated with subclinical Cushing's disease: a case report. ( 28865461 )
2017
19
Incidental pituitary adenoma detected by (18)F-FDG PET/CT and (18)F-choline PET/CT in the same patient. ( 28800881 )
2017
20
Hepatocellular adenoma in a European flatfish (Limanda limanda): Genetic alterations in laser-capture micro-dissected tissue and global transcriptomic approach. ( 28473212 )
2017
21
Clinicopathologic and Surgical Study of Pleomorphic Adenoma of the Parotid Gland: Analysis of Risk Factors for Recurrence and Facial Nerve Dysfunction. ( 28863883 )
2017
22
Metastasizing pleomorphic adenoma of the parotid gland. ( 28900471 )
2017
23
'Coexisting pituitary adenoma and suprasellar meningioma-a coincidence or causation effect: report of two cases and review of the literature'. ( 28560021 )
2017
24
Signal transducer and activator of transcription 3 (STAT3) promoter methylation and expression in pituitary adenoma. ( 28709401 )
2017
25
T cell lymphoblastic lymphoma/leukemia within an adrenocorticotropic hormone and thyroid stimulating hormone positive pituitary adenoma: A cytohistological correlation emphasizing importance of intra-operative squash smear. ( 28295636 )
2017
26
Fatal Mycotic Aneurysm of the Basilar Artery Caused by Aspergillus fumigatus in a Patient with Pituitary Adenoma and Meningitis. ( 28770205 )
2017
27
Pleomorphic adenoma gene like-2 induces epithelial-mesenchymal transition via Wnt/I^-catenin signaling pathway in human colorectal adenocarcinoma. ( 28259923 )
2017
28
Parathyroid adenoma with concurrent toxic thyroid adenoma: a rare combination. ( 28876558 )
2017
29
RIZ1 and histone methylation status in pituitary adenomas. ( 28718376 )
2017
30
Abdominal fat distribution measured using computed tomography is associated with an increased risk of colorectal adenoma in men. ( 28906398 )
2017
31
Simultaneous Occurrence of a Pituitary Adenoma and a Foramen Magnum Meningioma: Case Report. ( 27989978 )
2017
32
The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome. ( 28695322 )
2017
33
Cap cuff-assisted colonoscopy versus standard colonoscopy for adenoma detection: a randomized back-to-back study. ( 28082115 )
2017
34
Argininosuccinate synthase 1 (ASS1): A marker of unclassified hepatocellular adenoma and high bleeding risk. ( 28646562 )
2017
35
Synchronous contralateral pleomorphic adenoma of the parotid gland and submandibular gland. ( 27914682 )
2017
36
Diagnostic accuracy of virtual non-contrast enhanced dual-energy CT for diagnosis of adrenal adenoma: A systematic review and meta-analysis. ( 28289937 )
2017
37
A Model-Based Prediction of the Probability ofA HepatocellularA Adenoma and Focal Nodular HyperplasiaA BasedA on Characteristics on Contrast-EnhancedA Ultrasound. ( 28743375 )
2017
38
Metabolically-healthy obesity is associated with higher prevalence of colorectal adenoma. ( 28636624 )
2017
39
A novel cytogenetic and molecular characterization of renal metanephric adenoma: Identification of partner genes involved in translocation t(9;15)(p24;q24). ( 28595733 )
2017
40
An intrasellar pituitary adenoma-gangliocytoma presenting as acromegaly. ( 28469929 )
2017
41
Molecular characteristics of the KCNJ5 mutated aldosterone-producing adenomas. ( 28747387 )
2017
42
Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation. ( 28903326 )
2017
43
Seeding of a Pituitary Adenoma or Atypical Pituitary Carcinoma? ( 28589060 )
2017
44
Temporal and spatial changes of cells positive for stem-like markers in different compartments and stages of human colorectal adenoma-carcinoma sequence. ( 28484082 )
2017
45
Low Grade Carcinoma Ex-Pleomorphic Adenoma: Diagnosis and Diagnostic Challenges Caused by Fine Needle Aspiration: Report of Three Cases and Review of Literature. ( 28589437 )
2017
46
Aberrant G protein-receptor expression is associated with DNA methylation in aldosterone-producing adenoma. ( 28870781 )
2017
47
Middle ear adenoma with uncommon presentation and literature review. ( 28611057 )
2017
48
Ectopic Parathyroid Adenoma Presenting as a Mediastinal Mass. ( 28658791 )
2017
49
Nephrogenic adenoma does not express NKX3.1. ( 28581204 )
2017
50
Intraoperative Ultrasound in Patients Undergoing Transsphoidal Surgery for Pituitary Adenoma: Systematic Review. ( 28736351 )
2017

Variations for Adenoma

Expression for Adenoma

Search GEO for disease gene expression data for Adenoma.

Pathways for Adenoma

Pathways related to Adenoma according to GeneCards Suite gene sharing:

(show all 31)
id Super pathways Score Top Affiliating Genes
1 12.6 AXIN2 CCND1 CTNNB1 GNAS KRAS PRL
2
Show member pathways
12.33 BRAF CTNNB1 GNAS KRAS
3 12.32 CCND1 CTNNB1 KRAS SMAD4 TGFBR2
4
Show member pathways
12.31 AXIN2 BRAF CCND1 CTNNB1 KRAS MLH1
5 12.29 AXIN2 BRAF CCND1 CTNNB1 GNAS KRAS
6
Show member pathways
12.28 AXIN2 CTNNB1 GNAS KRAS
7 12.21 BRAF CCND1 CTNNB1 KRAS
8 12.02 AXIN2 CCND1 CTNNB1 SMAD4 TGFBR2
9 12 AXIN2 CTNNB1 KRAS SMAD4
10 11.98 CCND1 KRAS MLH1 MSH2
11
Show member pathways
11.94 BRAF CCND1 KRAS SMAD4 TGFBR2
12 11.9 CCND1 CTNNB1 KRAS SMAD4
13 11.89 BRAF CCND1 CTNNB1 KRAS MSH2 SMAD4
14 11.87 BRAF CCND1 CTNNB1 KRAS
15 11.8 BRAF CTNNB1 GNAS
16 11.79 CCND1 KRAS SMAD4 TGFBR2
17 11.78 CCND1 CTNNB1 SMAD4
18 11.78 BRAF KRAS SMAD4 TGFBR2
19
Show member pathways
11.73 BRAF KRAS RET
20 11.7 AXIN2 CCND1 CTNNB1
21 11.66 BRAF CCND1 KRAS
22 11.64 CTNNB1 SMAD4 TGFBR2
23 11.55 BRAF GNAS KRAS
24 11.54 AXIN2 BRAF CCND1 CTNNB1 GNAS KRAS
25 11.53 CTNNB1 SMAD4 TGFBR2
26 11.48 AXIN2 CCND1 CTNNB1
27 11.45 CTNNB1 SMAD4 TGFBR2
28 11.35 AIP KRAS PLAGL1 RET
29 11.1 CTNNB1 KRAS SMAD4 TGFBR2
30 11.01 AXIN2 CCND1 CTNNB1
31 10.76 CTNNB1 SST

GO Terms for Adenoma

Cellular components related to Adenoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 beta-catenin destruction complex GO:0030877 8.62 AXIN2 CTNNB1

Biological processes related to Adenoma according to GeneCards Suite gene sharing:

(show all 18)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.93 AXIN2 CTNNB1 SMAD4 SST TGFBR2
2 positive regulation of gene expression GO:0010628 9.91 BRAF CTNNB1 KRAS PLAG1 RET
3 regulation of cell proliferation GO:0042127 9.87 BRAF CTNNB1 SMAD4 TGFBR2
4 in utero embryonic development GO:0001701 9.83 CTNNB1 MSH2 SMAD4 TGFBR2
5 female pregnancy GO:0007565 9.75 GNAS KRAS PRL
6 positive regulation of isotype switching to IgG isotypes GO:0048304 9.56 MLH1 MSH2
7 positive regulation of cAMP-mediated signaling GO:0043950 9.55 GNAS LHCGR
8 response to steroid hormone GO:0048545 9.5 CCND1 SST TGFBR2
9 hair follicle placode formation GO:0060789 9.49 CTNNB1 GNAS
10 trachea formation GO:0060440 9.48 CTNNB1 TGFBR2
11 maintenance of DNA repeat elements GO:0043570 9.46 AXIN2 MSH2
12 somatic recombination of immunoglobulin gene segments GO:0016447 9.43 MLH1 MSH2
13 response to drug GO:0042493 9.43 CCND1 CTNNB1 GNAS RET SST TGFBR2
14 positive regulation of isotype switching to IgA isotypes GO:0048298 9.4 MLH1 MSH2
15 trachea morphogenesis GO:0060439 9.37 CTNNB1 TGFBR2
16 regulation of centromeric sister chromatid cohesion GO:0070602 9.26 AXIN2 CTNNB1
17 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.16 MLH1 MSH2
18 positive regulation of epithelial to mesenchymal transition GO:0010718 8.92 AXIN2 CTNNB1 SMAD4 TGFBR2

Molecular functions related to Adenoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 mismatched DNA binding GO:0030983 9.16 MLH1 MSH2
2 guanine/thymine mispair binding GO:0032137 8.96 MLH1 MSH2
3 I-SMAD binding GO:0070411 8.8 AXIN2 CTNNB1 SMAD4

Sources for Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO